RepliCel hair cell replication therapy
Phase 1- Indications
- Androgenetic alopecia, Pattern baldness
Company intelligence / Profile preview
TrichoScience Innovations
Vancouver, Canadasec.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Developed autologous cell therapies for hair regeneration and skin rejuvenation. Phase-1 trials showed safety and early efficacy signals. Partnered with Shiseido for Asian commercialization.
- Therapeutic areas
- DermatologyRheumatology
- Modalities
- Autologous cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Shiseido
Beyond the preview
Go deeper on TrichoScience Innovations.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TrichoScience Innovations.